Statistical considerations in the design,analysis and interpretation of clinical studies that use patient-reported outcomes *

Abstract

Get full access to this article

View all access options for this article.

References

United States Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (2009, accessed 25 February 2013).

Julious

Walters

. Estimating effect sizes for health-related quality of life outcomes. Stat Methods Med Res 2014; 23: 430–439.

Izem

Kammerman

Komo

. Statistical challenges in drug approval trials that use patient-reported outcomes. Stat Methods Med Res 2014; 23: 398–408.

Massof

. A general theoretical framework for interpreting patient-reported outcomes estimated from ordinally scaled item responses. Stat Methods Med Res 2014; 23: 409–429.

Cappelleri

Bushmakin

. Interpretation of patient-reported outcomes. Stat Methods Med Res 2014; 23: 460–483.

Bell

Fairclough

. Practical and statistical issues in missing data for longitudinal patient reported outcomes. Stat Methods Med Res 2014; 23: 440–459.

Panel on Handling Missing Data in Clinical Trials; National Research Council. The prevention and treatment of missing data in clinical trials, Washington, DC: National Academies Press, 2010.

United States Food and Drug Administration. Guidance for industry: clinical studies section of labeling for human prescription drug and biological products – content and format, http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127534.pdf (2006, accessed 28 February 2013).

Redelmeier

Guyatt

Goldstein

. Assessing the minimal important difference in symptoms: A comparison of two techniques. J Clin Epidemiol 1996; 49: 1215–1219.

10.

United States Food and Drug Administration. Draft guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0044-gdl0001.pdf (2006, accessed 26 February 2013).

11.

International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Comments on the FDA Draft Guidance for industry – patient-reported outcome measures: use in medical product development to support labeling claims, http://www.ispor.org/workpaper/ISPOR%20Response%20to%20FDA%20PRO%20Guidance.pdf (2006, accessed 26 February 2013).

12.

Bjorner JB, Gandek B, Cole J, et al. Response to the FDA Draft Guidance for industry document: patient-reported outcome measures: use in medical product development to support labeling claims (Docket 2006D-0044), http://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1610&context=qhs_pp (2006, accessed 26 February 2013).

13.

UCB, Inc. Comment on draft guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, http://www.fda.gov/ohrms/dockets/dockets/06d0044/06d-0044-c000004-01-vol1.pdf (2006, accessed 25 February 2013).

14.

United States Food and Drug Administration. Draft guidance: qualification process for drug development tools, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf (2012, accessed 25 February 2013).

15.

European Medicines Agency. Qualification of novel methodologies for drug development, http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf (2009, accessed 25 February 2013).

16.

Coons

Kothari

Monz

. The Patient-Reported Outcome (PRO) Consortium: filling measurement gaps for PRO endpoints to support labeling claims. Clin Pharmacol Therap 2011; 90: 743–748.

17.

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Reflection Paper on the Regulatory Use of Health Related Quality of Life (HRQL) measures in the evaluation of medicinal products, Committee for Medicinal Products for Human Use http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf (2009, accessed 25 February 2013).